This stock has been firing on all cylinders -- and it isn't about to stop.
The pharmaceutical giant gets a lift from some good news on insurance coverage and a prognosticator's price-target lift.
/PRNewswire/ -- Accolade (Nasdaq: ACCD) announced today findings from an employer survey on sentiment and adoption of GLP-1 medications. A key finding: while...
The company's fiscal 2024 second-quarter numbers showed improvement, but analysts and investors were not impressed.
/PRNewswire/ -- Accolade (Nasdaq: ACCD) announced the expansion of its care delivery team, strengthening the company's ability to streamline healthcare...
The widely followed growth investor went stock shopping on the final trading day in August.
The famous growth investor has been making some interesting stock moves lately.